tamatinib-resistant FLT3 mutants

Stable Identifier
R-HSA-9703009
Type
Pathway
Species
Homo sapiens
Locations in the PathwayBrowser
General
SVG |   | PPTX  | SBGN
Click the image above or here to open this pathway in the Pathway Browser

Tamatinib is a type I tyrosine kinase inhibitor with activity against FLT3. This pathway describes FLT3 mutants that are resistant to inhibition by tamatinib (Nguyen et al, 2017).

Literature References
PubMed ID Title Journal Year
28077790 FLT3 activating mutations display differential sensitivity to multiple tyrosine kinase inhibitors

Nguyen, B, Williams, AB, Young, DJ, Ma, H, Li, L, Levis, M, Brown, P, Small, D

Oncotarget 2017
Participants
Participant Of
Disease
Name Identifier Synonyms
cancer 162 malignant tumor, malignant neoplasm, primary cancer
Authored
Reviewed
Created
Cite Us!